Alembic Pharma receives approval for Teriflunomide tablets
Alembic Pharma receives approval for Teriflunomide tablets

Alembic Pharma receives approval for Teriflunomide tablets

Advait Dharmadhikari Article rating: 5.0

Alembic Pharma announced that the company has received approval from the USFDA for its Abbreviated New Drug Application (ANDA) Teriflunomide Tablets, 7 mg and 14 mg. The approved ANDA is therapeutically equivalent to the reference listed drug(RLD), Aubagio Tablets, 7 mg and 14 mg, of Sanofi- Aventis. Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Shital Jibhe Article rating: 5.0

The markets on April 22, 2019 opened gap down. BSE Sensex is trading at 38,827.25, down by 313.03 points and the Nifty is trading at 11,646.15, down by 106.65 points. 

Adani Enterprises subsidiary gains control of Alpha Design
Adani Enterprises subsidiary gains control of Alpha Design

Adani Enterprises subsidiary gains control of Alpha Design

Advait Dharmadhikari Article rating: 5.0

Adani Enterprises’ wholly-owned subsidiary Adani Defence Systems and Technologies has acquired the control of Alpha Design Technologies. Alpha Design Tech provides Adani Defence and Aerospace a strong Tier I capability for building a base for graduating to platform capabilities.

Shilpa Medicare surges on USFDA approval for Busulfan inj
Shilpa Medicare surges on USFDA approval for Busulfan inj

Shilpa Medicare surges on USFDA approval for Busulfan inj

Apurva Joshi Article rating: 5.0

Shilpa Medicare has received USFDA approval for its ANDA, Busulfan injection, 60 mg/10 ml on April 18, 2018. According to IQVIA MAT Q4 2018 data, the US market for Busulfan injection, 60 mg/10 ml is approximately US$32.8 million.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 3.28 crore contracts with a turnover of Rs. 21,63,258.86 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 3.28 crore contracts with a turnover of Rs. 21,63,258.86 crore.

Index trend and stocks in action April 22, 2019
Index trend and stocks in action April 22, 2019

Index trend and stocks in action April 22, 2019

Karan Dsij Article rating: 4.5

The bulls need to protect Tuesday’s session gap area of 11,705-11,732. On the higher side, the level of 11,800 is likely to act as a point of control and above this level, the bulls are likely to continue the rally. However, if it does not move above the 11,800 level, we expect some consolidation and some back and forth movement. Stocks in news: Avantel, Shilpa Medicare, Gravita India, The Shipping Corporation of India, Trigyn Technologies, Asian Granito.

Subdued opening likely following muted cues from Asian peers
Subdued opening likely following muted cues from Asian peers

Subdued opening likely following muted cues from Asian peers

Karan Dsij Article rating: 5.0

The Indian equity markets will re-open after a long weekend and markets will first react to earnings of index bigwigs such as Reliance Industries and HDFC Bank.  While there are no clear cues from the global peers, we expect markets to begin on muted note as, at the time of writing, SGX Nifty was trading down by 9 points at 11,799.

RSS
First23922393239423952397239924002401Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR